Alemtuzumab and prescription medication use in the MS population

Anibal Chertcoff, Huah Shin Ng, Feng Zhu, Yinshan Zhao, Elaine Kingwell, Helen Tremlett

Research output: Contribution to journalArticlepeer-review


Medications are indicated to minimize adverse reactions with alemtuzumab treatment for multiple sclerosis, but polypharmacy can be problematic. We characterized prescriptions filled by 160 individuals before, during and after first infusion of alemtuzumab (Dec/2013-Jun/2017). Ninety-five percent of individuals filled ≥1 prescription(s) before alemtuzumab across 87 unique drug classes, averaging 5.3 prescriptions/person over 47 weeks. During the infusion period, 90% filled ≥1 prescription(s) for 40 new drug classes, averaging 2.2 prescriptions/person over 5 weeks. Twenty-four percent refilled ≥1 of these prescription(s) after alemtuzumab across 17 drug classes, averaging 0.3 refills/person over 24 weeks. There was substantial medication burden throughout the study.

Original languageEnglish
Article number102086
Number of pages3
JournalMultiple Sclerosis and Related Disorders
Publication statusPublished - Jul 2020
Externally publishedYes


  • Alemtuzumab polypharmacy
  • Drug safety
  • Multiple sclerosis
  • Pharmacoepidemiology


Dive into the research topics of 'Alemtuzumab and prescription medication use in the MS population'. Together they form a unique fingerprint.

Cite this